Peter J. Goss Comments on Philadelphia Risperdal Verdict

Peter Goss commented for Law360 on the implications of a $2.5 million Philadelphia County  jury award for Johnson & Johnson’s defense of other Risperdal personal injury claims in other parts of the country.  “I would not make any predictions about what will happen elsewhere based on this Philadelphia County verdict,” Goss said. “J&J faced an uphill battle when the court limited their expert’s testimony regarding Risperdal’s FDA approvals and the corresponding benefits of the drug. Plus, plaintiffs were allowed to introduce a new causation expert in the middle of trial. J&J may not have to face the same handicaps in other jurisdictions, and a defense verdict may be attainable elsewhere, or possibly even in future Philadelphia County cases.”  The article is available to Law360 subscribers here.

Mr. Goss focuses his national practice on pharmaceutical and medical device product liability litigation and toxic torts. He has represented major pharmaceutical, medical technology, and chemical firms in hundreds of cases. Mr. Goss, who has won several published Daubert decisions, often serves as “science counsel” in life sciences litigation. He collaborates with leading experts to present complex medical and scientific evidence, both in dispositive motions and at trial. He is a frequent commentator on scientific evidence and legal developments of interest to FDA-regulated industries.

Blackwell Burke P.A., a litigation and trial boutique in Minneapolis, Minnesota, serves as national trial and litigation counsel for numerous Fortune 500 companies. The firm has extensive experience in class action defense, commercial litigation, food industry defense, labor and employment, and products liability. The firm has represented corporate clients in practically every jurisdiction in the country, as well as several foreign countries.

For more information about Blackwell Burke P.A. or Mr. Goss, please contact Kandy Branch at 612-343-3235 or kbranch@blackwellburke.com